Vitiligo

What it is

Vitiligo is a chronic autoimmune condition affecting approximately 1 to 2% of the global population — roughly 70 million people worldwide — in which the immune system destroys melanocytes, the pigment-producing cells of the skin, resulting in depigmented white patches on the skin, hair, and sometimes mucous membranes. Also called vitiligo vulgaris in its most common generalized form, the condition is not contagious, not caused by any external substance, and carries no increased risk of skin cancer in unaffected areas. Its impact is primarily cosmetic, but that framing understates its significance: vitiligo has a well-documented and substantial effect on quality of life, self-esteem, and mental health — particularly in people with darker skin tones, where the contrast between affected and unaffected skin is more pronounced.

In Canada, vitiligo affects people of all ethnicities and ages, with onset most common before age 30. Because vitiligo shares genetic risk factors with several other autoimmune conditions — including thyroid disease and type 1 diabetes — a new diagnosis warrants autoimmune screening, which in most provinces can be ordered through a family physician and processed at labs such as LifeLabs or Dynacare.

Vitiligo most commonly appears on the face (around the eyes and mouth), hands, wrists, forearms, genitalia, and areas around body openings. Hair, eyelashes, and eyebrows within affected areas may also turn white.

Causes and mechanism

Vitiligo results from a complex interaction of genetic predisposition, immune dysregulation, and environmental triggers.

The central mechanism is autoimmune: cytotoxic CD8+ T-lymphocytes recognize and destroy melanocytes in genetically susceptible individuals. Interferon-gamma then activates the JAK-STAT signalling pathway, amplifying the immune attack — a discovery that has become the basis for the newest class of vitiligo treatments. Melanocytes are also unusually vulnerable to oxidative stress; elevated hydrogen peroxide in affected skin contributes to both cell death and further immune activation.

Genetic factors are substantial. Having a first-degree relative with vitiligo meaningfully raises personal risk, and genome-wide association studies have identified multiple susceptibility genes, many of which overlap with genes linked to other autoimmune conditions.

Recognized triggers include:

• Physical trauma (Koebner phenomenon): skin injury at a site can trigger new vitiligo patches in predisposed individuals
• Psychological stress: a well-established trigger for both onset and worsening
• Sunburn: UV damage to melanocytes may precipitate new lesions

Vitiligo has a significantly elevated co-occurrence with thyroid disorders (Hashimoto's thyroiditis and Graves' disease), type 1 diabetes, Addison's disease, pernicious anaemia, and alopecia areata — conditions that share overlapping immune pathways.

Symptoms and diagnosis

The hallmark of vitiligo is flat, sharply demarcated white or pale cream patches with clearly defined borders. Patches are not itchy, painful, or inflamed in most cases, though edges may occasionally be slightly red or hyperpigmented. Hair within patches may turn white. Patches can remain stable for years or spread unpredictably.

The two main types:

Feature	Non-segmental (generalized)	Segmental
Prevalence	~90% of cases	~10% of cases
Distribution	Symmetrical, both sides of body	Unilateral, dermatomal
Onset	Any age	More common in children
Stability	Variable; can spread	Often more stable
Treatment response	Responds to phototherapy and JAK inhibitors	Responds well to surgical options

Diagnosis is usually clinical. A Wood's lamp (UV light) makes patches appear bright white-blue, helping identify early or subtle lesions. Skin biopsy is occasionally used to confirm the absence of melanocytes. At diagnosis, autoimmune screening is recommended: TSH, free T4, thyroid antibodies, fasting glucose, vitamin B12, full blood count, and ANA.

Treatment options

Treatment goals are to halt progression and restore pigmentation where possible. Several effective options now exist, including a first-in-class mechanism-based topical therapy approved in 2022.

Topical treatments:

• Topical corticosteroids: first-line for localized, active vitiligo; most effective on the face and early lesions
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus): preferred for sensitive areas such as the face and skin folds; avoid steroid-related side effects with long-term use
• Topical ruxolitinib (Opzelura): a JAK1/2 inhibitor cream approved by the FDA in 2022 for non-segmental vitiligo in adults and adolescents 12 and older; clinical trials showed significantly greater repigmentation than any previous topical agent (as of 2025, Health Canada approval status should be confirmed with a prescribing dermatologist)

Phototherapy:

• Narrowband UVB (nbUVB): the most widely used treatment for widespread vitiligo; typically administered 2 to 3 times per week; most effective on the face and trunk; combines well with topical treatments
• Excimer laser: targeted high-intensity UV for localized patches

Systemic treatments:

• Oral JAK inhibitors: under active clinical investigation for widespread disease; showing promising results
• Short-course oral corticosteroids: used to halt rapid progression

Surgical options (for stable, segmental disease):

• Melanocyte transplantation and skin grafting for small, stable patches

Supportive care:

• Broad-spectrum sunscreen (SPF 30 or higher) is essential — depigmented skin has no melanin protection against UV
• Camouflage cosmetics and self-tanning products for cosmetic coverage
• Psychological support and peer groups; mental health care is a recognized component of comprehensive vitiligo management

When to see a clinician in Canada

See a dermatologist or family physician if you notice white or pale patches appearing on the skin, especially if they are spreading, located around the eyes, mouth, hands, or genitalia, or accompanied by premature whitening of hair or lashes. Referral to a dermatologist is appropriate for most new diagnoses; wait times vary by province, and some Canadians access initial assessment through virtual care platforms (Maple, Dialogue, or similar services) while awaiting specialist referral.

At diagnosis, ask your physician about autoimmune screening — thyroid disease and type 1 diabetes in particular are common co-occurring conditions that benefit from early detection. If vitiligo is causing significant psychological distress, mental health support is an important part of management and may be accessible through provincial mental health programs or employee assistance plans.

Limitations and open questions

Research is still emerging on several fronts. The precise autoantigen that triggers CD8+ T-cell attack on melanocytes has not been fully characterized. The long-term durability of repigmentation achieved with JAK inhibitors — and what happens when treatment is stopped — is not yet established from extended follow-up data. Health Canada had not issued a specific approval for topical ruxolitinib as of early 2025; Canadian patients should confirm current regulatory and provincial formulary status with their dermatologist. The role of the gut microbiome and hormonal factors (including DHEA and thyroid hormones) in vitiligo activity is an active area of investigation but not yet clinically actionable. Optimal treatment sequencing, combination strategies, and maintenance protocols remain areas of active study without firm consensus guidelines.